PharmaFocus Today – Page 7 – media

Nobel Prize-winning company lays off 90% of its staff

Recently, Caribou Biosciences announced the termination of development of all its clinical pipelines, large-scale layoffs, and the initiation of a strategic review that includes mergers, acquisitions, and asset sales. Under California’s WARN Act, Caribou will lay off 87 employees, effective December 7. The company had 97 full-time employees as of February 27, 2026, meaning the layoffs will affect approximately 90% of its workforce . Caribou’s co-founders include Jennifer Doudna, a pioneer of CRISPR gene editing technology and the 2020 Nobel Prize laureate in Chemistry; the company was also one of the first to bring CRISPR to clinical application. From Nobel Prize Labs to Nasdaq In 2011 , Jennifer Doudna’s Berkeley lab had just unveiled the CRISPR-Cas9 gene-editing tool when she and her PhD student, Rachel Haurwitz, co-founded Caribou Biosciences, with venture capital firm Atlas Venture providing $11 million in seed funding. In 2014, Caribou, along with Atlas Venture, spun off ...
- Source: drugdu
- 118
- October 26, 2026
Methionine raw material passes South Korea’s MFDS inspection

Tianjin Pharmaceutical Co., Ltd.On the evening of October 23, the company issued a statement saying that it had recently received the results of a GMP on-site inspection from the Korean Ministry of Food and Drug Safety (MFDS). From September 8th to 10th, Tianjin Pharmaceutical Group’s production base located at No. 19, Xinyejiu Street, West Zone, Tianjin Economic-Technological Development Area, received methionine raw material.The site underwent GMP inspection and passed the Korean MFDS requirements with “zero defects”. Methionine, an essential amino acid for the human body, is a core raw material for various amino acid infusions and compound amino acid preparations. Clinically, it is used as an adjunct treatment for chronic hepatitis and cirrhosis, as well as a supportive treatment for toxic liver disease. Industry insiders believe that the scope of this inspection focused on methionine raw materials , and passing with “zero defects” means that the company’s quality system, production ...
- Source: drugdu
- 113
- October 26, 2026
Clinical trial application submitted to the US FDA for ASC39 oral tablets for the treatment of obesity.

People’s Finance News, October 26th – Ascletis Pharma announced on the Hong Kong Stock Exchange that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its ASC39 oral tablets. ASC39 is an oral, small-molecule selective amylin receptor agonist used to treat obesity. The company expects to initiate a Phase I trial in the fourth quarter of 2026. Source: https://finance.eastmoney.com/a/202610263907436177.html
- Source: drugdu
- 116
- October 26, 2026
FDA Approves Revolution Medicines’ Oral RAS Inhibitor Rasonque (daraxonrasib) for Metastatic Pancreatic Cancer

On October 19, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), an oral RAS inhibitor from Revolution Medicines, Inc., for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval is based on a randomized, open-label, multicenter trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. Participants received once-daily oral daraxonrasib or standard chemotherapy. The trial showed a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. Daraxonrasib targets multiple forms of the RAS protein, a key driver of tumor growth in most pancreatic adenocarcinomas, and the approved indication does not impose a biomarker-based eligibility criterion. The approval offers a new treatment option for pancreatic cancer patients, who have historically faced limited treatment choices and poor outcomes. The most common side effects reported with daraxonrasib included ...
- Source: drugdu
- 277
- October 20, 2026
Hansoh Pharma Enters Strategic ADC Collaboration with Roche Worth Over US$15.5 Billion

On the evening of October 19, 2026, Hansoh Pharmaceutical Group (03692.HK) announced that its wholly-owned subsidiaries Shanghai Hansoh Biomedical Co., Ltd., Changzhou Hansoh Pharmaceutical Co., Ltd. and Hansoh Bio, LLC (collectively, Hansoh) entered into a strategic collaboration and license agreement on October 17 with F. Hoffmann-La Roche Ltd. This marks the two companies’ second partnership in the antibody-drug conjugate (ADC) field. The collaboration spans a broad portfolio of ADC programs, comprising two preclinical Hansoh ADC programs and multiple ADC programs based on Roche-proposed targets and powered by Hansoh’s proprietary ADC technology platform. Under the agreement, Hansoh will lead the early development of the programs up to completion of global Phase Ia clinical trials, while Roche will be responsible for further worldwide development excluding the Chinese Mainland, Hong Kong, Macau and Taiwan. Hansoh retains all rights to develop, register and commercialize the programs within Greater China. Under the agreement, Hansoh will ...
- Source: drugdu
- 168
- October 20, 2026
New cough medicine launched

Recently, the National Medical Products Administration approved the marketing of Zihua Wenfei Zhike Granules , a Class 1.1 innovative traditional Chinese medicine submitted by Guangzhou Yuekang Biopharmaceutical Co., Ltd., a subsidiary of Yuekang Pharmaceutical , for the treatment of cough due to wind-cold lingering in the lungs . Cough is a common symptom of respiratory diseases, and post-infectious cough is particularly troublesome due to its prolonged course. Zihua Wenfei Zhike Granules are specifically indicated for cough due to wind-cold lingering in the lungs, providing a new medication option for patients with this syndrome whose illness lasts 3 to 6 weeks. From the perspective of the formulation, the product prescription is derived from an empirical formula that has been clinically verified over a long period of time . It is composed of six medicinal materials: Aster tataricus, Tussilago farfara, Belamcanda chinensis, dried ginger, mango kernel, and Schizonepeta tenuifolia. These herbs complement ...
- Source: drugdu
- 151
- October 20, 2026
Shining on the top stage! The world’s first three-target agonist DR10624 MASLD/MASH Phase II results were selected for the latest breakthrough abstract of AASLD.

On October 19, 2026, Huadong Medicine Co., Ltd. (hereinafter referred to as “Huadong Medicine”) announced that the results of the Phase II clinical trial (“DR10624-202 Study”) of DR10624, a first-in-class long-acting trispecific agonist independently developed by its holding subsidiary Zhejiang Daer Biotechnology Co., Ltd. (hereinafter referred to as “Daer Biotechnology”) for the treatment of metabolic-associated fatty liver disease (MASLD)/metabolic steatohepatitis (MASH), have been successfully selected as the Late Breaking Abstract (LBA) of The Liver Meeting® (TLM) 2026 of the American Association for the Study of Liver Diseases (AASLD) and will be presented in the form of a Late Breaking Parallel Presentation. The principal investigator of this study, Associate Vice-President (Research) and Professor Mok Hing-yiu of Medicine at the Chinese University of Hong Kong, along with Professor Wong Wai-sun, Assistant Dean (Development) of the Faculty of Medicine and Head of the Department of Gastroenterology and Hepatology, will deliver a presentation on ...
- Source: drugdu
- 269
- October 20, 2026
The world’s first long-acting anti-RSV monoclonal antibody has been commercially launched

Recently, the domestically developed long-acting anti-respiratory syncytial virus (RSV) monoclonal antibody, ritvirabimab injection (trade name: Newdox), was launched in Jinwan District, Zhuhai. This is the world’s first long-acting anti-RSV monoclonal antibody with 9 months of protection data after a single injection, and it was independently developed and produced by Zhuhai TechnoMed Pharmaceutical Co., Ltd. RSV is one of the most common pathogens causing lower respiratory tract infections in infants and young children. The risk of infection increases significantly during the autumn and winter seasons. It is often associated with diseases such as severe pneumonia and bronchiolitis, and poses a particularly prominent threat to premature infants, low birth weight infants, and infants with congenital cardiopulmonary diseases. Source: https://mp.weixin.qq.com/s?__biz=MzIxMjYwMDI5Nw==&mid=2247717580&idx=3&sn=3f2a07c30d243e6b52fc0aeb2869baee&chksm=96e51b57c73949dc987f0a25e6a5421a12bfd06db7332796d4078d21b0d18e20c36f3d42b430&scene=126&sessionid=0#rd
- Source: drugdu
- 127
- October 20, 2026
Lunan Pharmaceutical’s Weikangda® Tegafur Capsules Receive Marketing Approval in Pakistan

Recently, Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, received a drug registration certificate for Tegafur Capsules (Viconda®) issued by the Food and Drug Administration of Pakistan (DRAP) , marking that the product has officially obtained market access in Pakistan and can be sold and commercialized there. Tegafur capsules are a compound preparation composed of tegafur, gimeracil, and oteracil potassium. They can inhibit tumor cell proliferation, induce tumor cell apoptosis, enhance the effect of chemotherapy, and reduce the side effects of chemotherapy. They are mainly used to treat patients with unresectable locally advanced or metastatic gastric cancer. During the product’s market approval process in Pakistan, the registration team strictly adhered to local regulations and scientifically and rationally prepared technical documentation, ensuring the product’s successful approval. This provided local gastric cancer patients with a more efficient and accessible treatment option, and laid a solid foundation for subsequent ...
- Source: drugdu
- 145
- October 20, 2026
Announcement Regarding Nimodipine Tablets Passing the Generic Drug Consistency Evaluation

Securities Daily News, October 19th – Xinhua PharmaceuticalThe company announced that it recently received the “Approval Notice for Supplemental Application for Drug” for Nimodipine tablets issued by the National Medical Products Administration. The product has passed the consistency evaluation of generic drug quality and efficacy. The specification is 30mg. This product is used as a continuation treatment after prior use of Nimodipine injection, and can prevent and treat ischemic neurological injury caused by cerebral vasospasm following aneurysmal subarachnoid hemorrhage. It belongs to Category A of the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2025)”. Source: https://finance.eastmoney.com/a/202610193900147785.html
- Source: drugdu
- 132
- October 20, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.